Non‐severe COVID‐19 is associated with endothelial damage and hypercoagulability despite pharmacological thromboprophylaxis
Sarah Kelliher, Luisa Weiß, Sarah Cullivan, Ellen O’Rourke, Claire Murphy, Shane Toolan, Áine Lennon, Paulina B. Szklanna, Shane P. Comer, Hayley Macleod, Ana Le Chevillier, Seán Gaine, Kate M.A. O’Reilly, Brian McCullagh, John Stack, Patricia B. Maguire, Fionnuala Ní Áinle, Barry Kevane
Topics & Concepts
MedicineHeparinInternal medicineCoronavirus disease 2019 (COVID-19)ThrombosisGastroenterologyEndothelial dysfunctionPlasminogen activator inhibitor-1CoagulopathyImmunologyPlasminogen activatorDiseaseInfectious disease (medical specialty)COVID-19 Clinical Research StudiesHeparin-Induced Thrombocytopenia and ThrombosisLong-Term Effects of COVID-19